drugset / Trial / NCT00118313
Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
Open-labelTreatment
Summary
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Biological therapies, such as imiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. Giving vaccine therapy together with imiquimod after surgery may help the body kill any remaining tumor cells. PURPOSE: This randomized phase I trial is studying the side effects and best way to give vaccine therapy with or without imiquimod in treating patients who have undergone surgery for stage II, stage III, or stage IV melanoma.
Timeline
- Start
- 2004-11-04
- Primary completion
- 2006-07-28
- Completion
- 2006-07-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imiquimod | Other / unclassified | — | Topical |
| Subject | dimethyl sulfoxide | Small molecule | — | Other |
| Subject | multi-epitope melanoma peptide vaccine | Vaccine | — | Other |
| Subject | sargramostim | Protein / enzyme biologic | — | Other |
| Subject | tetanus toxoid helper peptide | Peptide | — | Other |
| Background | incomplete Freund's adjuvant | Other / unclassified | — | — |